In its short term at the stock market, Beyond Meat (NASDAQ: BYND) has joined the elite league of companies that constantly leave the Wall Street astounded with its performance. Despite its unprofitability, over-the-top valuation, and high short interest, the stock continues its stoic upward trajectory.
Today, the stock once again gained over 15% before the opening bell, adding to yesterday’s gains on reports that it would start selling its plant-based ground beef products at Kroger, Whole Foods and HEB stores. The stock gain has once again left shorts burning.
Credit Suisse has the highest price target of $125 on the stock. BYND stock is, meanwhile, currently trading 36% above this price. The most bearish rating firm is Goldman Sachs, with a price target of $76, way below the current trading price.
Even as there is a wide variation in the price targets set by different analysts, all of them converge on their neutral ratings. J.P. Morgan and Bernstein were the only two firms with a Buy rating, but they also downgraded last week and joined the neutral squad.
READ: Beyond Meat Q1 loss widens but guides 2019 revenue above consensus
The market and customers are pretty happy about Beyond Meat’s products. The investments into R&D have paid off and its products taste pretty much like real meat. However, with a price to sales ratio at close to 90, the market is pretty worried about the company’s valuation.
Short sellers have suffered mark to market losses of as much as $560 million since BYND IPO. Over the last week, this has somewhat cut down the short interest on the stock.
Beyond Meat stock has increased 580% since its IPO in May.
Most Popular
United Parcel Service (UPS) seems on track to regain lost strength
Cargo giant United Parcel Service, Inc. (NYSE: UPS) ended fiscal 2023 on a weak note, reporting lower revenues and profit for the fourth quarter. The company experienced a slowdown post-pandemic
IPO Alert: What to look for when Boundless Bio goes public
Boundless Bio is preparing to debut on the Nasdaq stock market this week, and become the latest addition to the list of biotech firms that have launched IPOs this year.
Nike (NKE) bets on innovation and partnerships to return to high growth
Sneaker giant Nike, Inc. (NYSE: NKE) has been going through a rough patch for some time, with sales coming under pressure from weak demand and rising competition. Post-pandemic, the company
Comments